Trial Profile

An Investigational Study of CX-801 as Monotherapy and in Combination With PD1 Inhibition in Participants With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CX 801 (Primary) ; Pembrolizumab (Primary)
Indications Head and neck cancer; Malignant melanoma; Renal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; First in man
Sponsors CytomX Therapeutics

19 May 2025 According to a CytomX Therapeutics media release, company announced that the first patient has been dosed in this study.
12 May 2025 According to a CytomX Therapeutics media release, study is currently in the fourth monotherapy dose escalation cohort where the dose of CX-801 exceeds the approved dose of the unmasked peginterferon alfa-2b.
06 Mar 2025 According to a CytomX Therapeutics media release, Initial Phase 1a translational and biomarker data in advanced melanoma is expected in the second half of 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com